Submitted by kBLASTER Team on
By Stephanie Baum for MedCityNews.com
Medical device company Eko got the greenlight from the FDA with a 510(k) clearance for its Class 2 medical device — digital stethoscope Eko CORE, according to a company statement. It wirelessly streams heart sounds to a smartphone app and integrates heart sounds directly into the patient’s electronic health record. The goal is to support physicians treatment of patients with cardiovascular disease.
One of the cool thing about digital stethoscopes is that they can record patients’ heart sounds and make it easier for physicians to share them for consults, for example. The app, which is available from iTunes app store, also provides a view of waveform of the heart sounds. The device itself is expected to retail for $199.
Eko has had a collaboration with the University of California San Francisco’s Department of Cardiology, which has led Eko’s ongoing clinical trial. The trial will be expanded to Stanford University Department of Medicine where internal medicine residents will use the device as part of a pilot.
Another product Eko has in the works is Eko is a clinical decision support algorithm. It will be included with the mobile app after undergoing a separate FDA review and completing trials, according to the company statement.
Earlier this year Eko raised a $2.8 million funding round that included music identification company Shazam’s co-founders, FOUNDER.org Founder and CEO, Michael Baum, Stanford University StartX Fund, and former senior advisor to the U.S. Secretary of Health and Human Services, John Noonan.
kBLASTER® has more than 61,000 510(k) summaries and 76,000 510(k) splash pages to search for a primary predicate, multiple predicates or reference devices. kBLASTER® transforms result management with both speed and data science tools of sorting, My Favorites, Saved Search and Search History. kBLASTER® brings actionable insight to your mobile device, tablet or computer with interchangeable ease to convert your 510(k) challenge into a 510(k) solution.